The ABHD6 Knockout TE1 Polyclonal Cells are a human polyclonal knockout cell population derived from the TE1 esophageal squamous cell carcinoma cell line, engineered via CRISPR/Cas9-mediated disruption of the ABHD6 gene. This product provides a loss-of-function model to study ABHD6, a monoacylglycerol lipase that hydrolyzes 2-arachidonoylglycerol (2-AG), a key endocannabinoid. The polyclonal nature ensures a mixed population of edited cells, suitable for bulk biochemical, genomic, and functional analyses without clonal artifacts.
The TE1 host cell line is a widely used model of human esophageal squamous cell carcinoma, offering a relevant cellular context for studying oncogenic processes and metabolic reprogramming. Derived from a primary tumor, TE1 cells retain many characteristics of esophageal cancer and are frequently employed in investigations of signal transduction, invasion, and drug response. Their use in this knockout model allows direct interrogation of gene function within an esophageal cancer background.
ABHD6 encodes a serine hydrolase that terminates endocannabinoid signaling by converting 2-AG to arachidonic acid and glycerol. This reaction lies at the intersection of endocannabinoid, glycerolipid, and arachidonic acid metabolic pathways. ABHD6 activity is regulated by upstream factors such as PPAR??, insulin signaling, and substrate availability, and its products feed into the synthesis of prostaglandins and activate cannabinoid receptors CB1 and CB2. The enzyme associates with lipid droplets and functions alongside other lipases like MAGL and FAAH to control 2-AG tone.
In TE1 cells, ABHD6 knockout disrupts the conversion of 2-AG, potentially leading to accumulation of this endocannabinoid and altered signaling through CB1/CB2 receptors. Simultaneously, reduced arachidonic acid production may diminish downstream pro-inflammatory and pro-tumorigenic lipid mediators. This perturbation provides a platform to dissect how ABHD6-dependent lipid metabolism influences esophageal cancer cell proliferation, migration, and response to metabolic cues, linking endocannabinoid biology with oncogenic phenotypes.
Researchers can apply this model to explore endocannabinoid signaling in esophageal squamous cell carcinoma, investigate lipid-mediated regulation of tumor growth, and evaluate ABHD6 as a candidate therapeutic target. Typical experiments include measuring 2-AG hydrolysis activity, monitoring ABHD6 expression by RT-qPCR and Western blotting, performing lipidomics to profile lipid mediator changes, and assessing functional outcomes via cell proliferation, migration, and invasion assays. Additionally, RNA-seq and drug sensitivity profiling can reveal downstream transcriptomic and pharmacological consequences of ABHD6 loss. For further technical information, please contact Ascent Research.
